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The Challenge of Analyzing
the Results of Next-Generation
Sequencing in Children
Isabelle Thiffault, MSc, PhDa,b,c John Lantos, MDa,b,d

In recent years, next-generation sequencing technologies have revolutionized approaches
to genetic studies. Whole-exome or whole-genome sequencing allows diagnoses in many
patients who have complex phenotypes and unusual clinical presentations. As genomic and
exomic testing expands in both the research and clinical settings, pediatricians will need to
understand the technology of next-generation sequencing and the complexity of interpreting
genomic variants relevant to patient phenotypic features. This article briefly explains
the technology by which genomes are sequenced and discusses some of the complexity
related to interpreting genomic variants. We conclude with some thoughts on the clinical
applications of such testing.
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SUPPLEMENT ARTICLE

Clinical genetics is changing. Nextgeneration sequencing (NGS) of
DNA is slowly replacing traditional
technologies for the diagnosis of
genetic disorders. The key difference
between NGS and older technologies
is a matter of precision and scale.
NGS can precisely reveal multiple
variations in ∼19 000 genes
simultaneously. The challenge with
older technologies was in deciding
which variations to search for. The
challenge with NGS is in interpreting
the meaning of those variations in the
context of clinical care.
As the cost of NGS drops, it becomes
feasible to use this powerful
technology in clinical medical
practice. In some cases, this use
allows the diagnosis of rare disorders
that may not be diagnosable with
other methods.1 In other cases,
however, NGS generates confusing
results that are difficult to interpret
or use in a way that improves clinical
care. Because NGS tests for so many
things at once, it is unclear how to
assess its sensitivity, specificity,
accuracy, or clinical utility; or how
to compare it with more traditional
approaches.2
Diagnosis is a complex process.
It requires an accurate medical
history, a good physical examination,
laboratory tests, and imaging
studies. Even with these tactics,
however, clinical diagnosis often
remains elusive. The process of
extensive testing to diagnose rare
conditions has been referred to as
the “diagnostic odyssey.” Even when
the index of suspicion of a genetic
condition is very high, the process
may not yield a diagnosis.3–8
NGS adds an additional source of
data to the process of diagnosis. It
is clearly changing the diagnostic
paradigm. The success rate of NGS
for the identification of a causative
variant fluctuates considerably
between studies, however.3,5–18
Thus, many questions remain.
Which patients or diseases should
be prioritized for NGS analysis? Who
S4

should interpret the results and using
what criteria? How can we maximize
true-positive and -negative results
while avoiding false ones? Answers
to these questions are essential for
determining how best to use NGS in
conjunction with other diagnostic
approaches.
To help clinicians tackle these
challenges, the present article briefly
explains the technology of NGS
and offers our insights into how to
interpret NGS data in the context of
pediatric patients.

Technical Overview of NGS
The human genome has 6.2 billion
base pairs. Of the entire genome, only
∼1% codes for proteins; this 1% is
called the exome. The exome contains
∼85% of known or potential diseasecausing variants. It is organized into
∼19 000 genes, and these genes
contain the code for ≥1 protein.
The entire DNA content (coding and
noncoding) is called the genome.
Sequencing of the entire genetic code
of a person is called “whole-genome
sequencing”; sequencing parts of
the genome that contain genes is
called “whole exome sequencing.”
Whole-genome and whole exome
sequencing use the same laboratory
processes, which begin with the
extraction of DNA from cells
(usually white blood cells). After
extraction, the DNA is broken into
small fragments. These fragments
are then put through a process
called library preparation, a step
that is required for both the exome
and genome. For the exome, an
enrichment procedure is necessary
to “capture” only the information of
the exons (the expressed region);
that is, the protein-coding regions of
the genome. The enrichment step can
also be used for targeted gene panels.
This process allows sequencing of
only preselected genes.
The sequencing instrument “reads”
the genetic code of these short

sequences and generates millions of
short sequence reads. These short
sequence reads are then aligned and
matched to specific positions in the
human genome reference sequence
with the use of bioinformatic tools. A
computerized annotation of genotype
(A, C, G, or T) at each position in
the exome or genome is performed.
Similarities and differences between
the patient’s sequence and the
reference sequence can then be
highlighted.
To assure accuracy, the patient’s
genomic sequence is read multiple
times. This process allows a
quantification of the accuracy of the
genotype at each base pair position.
The next task is to determine which
variations in the patient’s genome,
compared with the reference
genome, may be clinically significant
or relevant.

Variants can be classified according
to frequency, type, and previous
reported association with particular
clinical conditions. Typically, the
file is filtered for rare variants (ie,
allele frequency inferior to 1% in
the general population) because
only rare variants are likely to
be pathogenic (variants that are
common in the general population
seldom cause rare Mendelian
disorders). Some variants are
known to be benign; others are of
a type that generally causes loss
of function or altered function of
a gene. Many variants have been
previously reported to cause disease,
but many others remain of unknown
clinical significance. Depending
on present knowledge, variant
analysis is imperfect, and the variant
interpretation does not imply 100%
certainty. The American College
of Medical Genetics and Genomics
offers guidelines for variant
interpretation.19
The yield of sequence reads is
inherently uneven across the exome
and genome. Typically, NGS results
provide adequate coverage of 85%
to 98% of the targeted sequence

Downloaded from www.aappublications.org/news by guest on October 10, 2018

Thiffault and Lantos

regions. The biggest challenges in
interpreting NGS results are not
a product of the inaccuracy of the
technology; they instead arise from
the difficulty in interpreting the
meaning of the numerous variants.

Interpretation of Variants
Variants can only be interpreted after
a good clinical history, family history,
and physical examination have
been performed. Data from these
preliminary steps allow physicians
to assess whether there are similar
or related phenotypes in other family
members; if so, the inheritance
pattern can then be evaluated and
assessed.
Physical examination findings
allow physicians to begin a search
for potentially relevant genes.
The patient should be examined
for “major features” of genetic
disease as well as other potentially
relevant “minor features.” The
Human Phenotype Ontology
(HPO) categorization aims to
provide a standardized vocabulary
of phenotypic abnormalities
encountered in human disease.
HPO currently contains ∼11 000
terms and >115 000 annotations to
hereditary diseases.20

Mode of inheritance and a
comprehensive phenotype can then
be used to review the published
literature and to search relevant
databases. Search engines include
tools such as Google and PubMed;
more specialized searching can use
tools such as Orphanet, DECIPHER,
and OMIM (Online Mendelian
Inheritance in Man).20 Bioinformatic
tools such as Phenomizer can help
develop a differential diagnosis using
HPO to identify candidate diseases/
disease genes that best explain a
patient’s set of clinical features.20,21
These tools allow some classification
of the patient’s genomic variants.
NGS may lead to the discovery of a
known pathogenic variant, a novel

pathogenic variant that is likely to
be disease-causing, or a variant of
unknown clinical significance in a
gene known to cause human disease.
Novel variants of unknown clinical
significance or apparently pathogenic
variants in genes not yet known
to cause human disease require
additional clinical and laboratory
research to judge the pathogenicity
of the variants. Freely accessible
Web sites such as GeneMatcher
are designed to enable connections
between clinicians and researchers
from around the world who share an
interest in the same gene or genes.
This availability allows matching
based on phenotypic features for
individuals with novel disorders or
novel clinical presentation with or
without candidate genes to enable
diagnosis for very rare cases.
Clinical validity is a complicated
and challenging aspect of NGS.
Evidence is required to prove that a
specific rare variant in a particular
gene, detected by NGS, is indeed
pathogenic and responsible for a
particular clinical phenotype.

NGS analysis is influenced by the
expected inheritance patterns
(autosomal dominant, recessive,
or X-linked) and whether other
family members are available for
phenotyping and genetic testing.
Biological parental testing is
important when a de novo variant
is suspected; if neither parent has
the variant, and biologic parentage
is confirmed by using rare singlenucleotide polymorphisms, the
variant is confirmed as de novo.
Recent studies suggest that up to
65% of diagnoses are associated with
a de novo variant.7,9,16,22

In other situations, NGS performed
in only 1 affected child, followed by
genotyping of just a few variants in
affected and unaffected relatives, may
show cosegregation of the variant
and the disease. These findings
support the pathogenicity of the
variant.8,12,16,19,22

Interpreting and Reporting NGS
Results
The most challenging aspect of NGS
testing is the analytic validity.19
The highest level of analytic validity
occurs when there is a variant in
a gene that has been previously
associated with the patient’s
condition and when functional test
results of that gene’s function exhibit
abnormalities. There are, however,
few functional studies of the effect of
individual variants in their biological
context. This limitation hampers
effective and comprehensive
interpretation.

The next level occurs when a variant
has been previously associated
with the patient’s condition but no
functional studies. These findings
must be interpreted cautiously,
however, because in databases (as
well as in literature), there are many
false attributions of disease-causing
variants. Rare nontruncating variants
(synonymous, nonsynonymous,
and noncoding variants) that have
been described as “pathogenic”
and associated with a phenotype
should be carefully interpreted for
their clinical significance.19 The
major challenge for interpreting and
reporting variants is the need for
critical and rigorous interpretation
of variants associated with clinical
indications. Several databases (eg,
the Human Gene Mutation Database,
ClinVar, the LOVD) document
disease-causing variants and attempt
to improve variant curation.
Clinicians reviewing NGS clinical
reports should apply critical thinking
and be aware of the possibility of
a false attribution of pathogenicity
to a variant. To achieve better
diagnostic accuracy, clinicians
should extensively review the
medical literature and consult with
experts in genomic analysis. Clinical
geneticists, molecular geneticists,
genetic counselors, and pediatric
subspecialists may all be helpful.
These experts can help a clinician
understand the acknowledged
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limitations of NGS. For example,
NGS is known to miss some
particular genetic variations, such
as trinucleotide repeat disorders,
mitochondrial DNA mutations, large
indels, translocation, and disorders of
epigenetic regulation.
Given the uncertainties regarding
the meaning of many NGS results,
NGS cannot be used as a substitute
for a careful clinical evaluation. The
interpretation of sequence variants
could be significantly improved
by encouraging data sharing and
transparent exchange of curated
variants associated with the
phenotype.

Clinical Use of NGS
NGS is likely to be used more in
pediatrics than in other clinical
settings, mainly because many
genetic conditions have a poor
prognosis and children who have
those conditions do not survive
until adulthood. Thus, pediatricians
need to be aware of the promise
and pitfalls of NGS and be prepared
to decide when it will be useful for
patients.

Recent studies suggest that less
than one-half of patients who
have genetic conditions are
diagnosed by using standard
genetic approaches.1,5,9,10,12,23 It
is possible that NGS will allow a
precise diagnosis in a much higher
percentage of infants.1,5,9,10,12,13,16,17,24
At present, many of those infants
will have conditions for which no
treatment exists. The major benefit
of an accurate diagnosis will be
to allow precise prognosis and
better-informed discussions about
the desirability of life-prolonging
treatment. To be better prepared
for these discussions, pediatricians
should be familiar with the
technology of testing, the ambiguities
in diagnosis, and the possibility for
false-positive and false-negative
findings that are associated with
different strategies for interpreting
S6

genomic variants. With such caveats,
NGS may prove useful in the care
of infants and children with rare
conditions that have not been
diagnosed with the use of more
traditional tests.
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